Skip to main content
WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
30.94
+0.12 (0.39%)
Aug 15, 2025, 4:08 PM HKT

WuXi Biologics Revenue

In the year 2024, WuXi Biologics had annual revenue of 18.68B CNY with 9.63% growth. WuXi Biologics had revenue of 10.10B in the half year ending December 31, 2024, with 25.29% growth.

Revenue
18.68B CNY
Revenue Growth
+9.63%
P/S Ratio
6.34
Revenue / Employee
1.49M CNY
Employees
12,575
Market Cap
125.94B HKD

Revenue Chart

* This company reports financials in CNY.

History

Fiscal Year End Revenue Change Growth
Dec 31, 202418.68B1.64B9.63%
Dec 31, 202317.03B1.77B11.56%
Dec 31, 202215.27B4.98B48.38%
Dec 31, 202110.29B4.68B83.35%
Dec 31, 20205.61B1.63B40.88%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
BeOne Medicines 35.81B
Hansoh Pharmaceutical Group Company 13.05B
JD Health International 71.34B
Innovent Biologics 10.03B
Akeso 2.26B
Sino Biopharmaceutical 30.72B
CSPC Pharmaceutical Group 28.99B
Sichuan Kelun-Biotech Biopharmaceutical 2.06B
Revenue Rankings

WuXi Biologics News

More News